Summit Therapeutics Inc [SMMT] stock is trading at $19.09, down -0.21%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The SMMT shares have gain 5.41% over the last week, with a monthly amount drifted -11.21%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Summit Therapeutics Inc [NASDAQ: SMMT] stock has seen the most recent analyst activity on February 28, 2025, when Goldman initiated its Buy rating and assigned the stock a price target of $42. Previously, Truist started tracking the stock with Buy rating on January 08, 2025, and set its price target to $35. On December 11, 2024, Wells Fargo initiated with a Overweight rating and assigned a price target of $30 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $31 on December 06, 2024. JMP Securities initiated its recommendation with a Mkt Outperform and recommended $32 as its price target on November 04, 2024. Citigroup downgraded its rating to Neutral for this stock on September 27, 2024, and upped its price target to $23. In a note dated August 12, 2024, H.C. Wainwright initiated an Buy rating and provided a target price of $16 on this stock.
Summit Therapeutics Inc [SMMT] stock has fluctuated between $2.10 and $33.89 over the past year. Currently, Wall Street analysts expect the stock to reach $35 within the next 12 months. Summit Therapeutics Inc [NASDAQ: SMMT] shares were valued at $19.09 at the most recent close of the market. An investor can expect a potential return of 83.34% based on the average SMMT price forecast.
Analyzing the SMMT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.51, Equity is -0.83 and Total Capital is -0.54. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.50 points at the first support level, and at 17.90 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.53, and for the 2nd resistance point, it is at 19.96.
Ratios To Look Out For
For context, Summit Therapeutics Inc’s Current Ratio is 10.15. In addition, the Quick Ratio stands at 10.15 and the Cash Ratio stands at 2.51.
Transactions by insiders
Recent insider trading involved Zanganeh Mahkam, Chief Executive Officer, that happened on Mar 27 ’24 when 54321.0 shares were purchased. Chief Executive Officer, Zanganeh Mahkam completed a deal on Mar 26 ’24 to buy 30000.0 shares. Meanwhile, Chief Executive Officer Zanganeh Mahkam bought 26000.0 shares on Mar 27 ’24.
